Molecular mechanisms and treatment responses of pulmonary fibrosis in severe COVID-19

Respiratory Research

Table 1 Patient characteristics of the pre-DEXA- and DEXA-cohorts

	Pre-DEXA-cohort (n = 67)	DEXA-cohort (n = 124)	p-value
Age, years	65 [58–72]	65 [56–72]	0.89
Sex, male	50 (75)	84 (68)	0.41
BMI, kg/m²	27.7 [24.9–30.8]	29.4 [26.2–33.3]	0.005
APACHE II	15 [12–19]	16 [13–20]	0.08
Days first COVID-19 signs until ICU admission	11 [7–13]	10 [7–12]	0.46
Medical history
Renal insufficiency	1 (1)	3 (2)	1.00
Metastatic neoplasm	5 (7)	2 (2)	0.053
Immunological insufficiency	1 (1)	6 (5)	0.43
COPD	6 (9)	13 (10)	0.81
Diabetes mellitus	15 (22)	32 (26)	0.73
Hypertension	33 (49)	63 (51)	0.88

Data presented as n (%) or median with interquartile ranges ([IQR]). P-values were calculated using Mann–Whitney U and two-sided Fisher’s exact tests for continuous and categorical data, respectively
DEXA dexamethasone, PF pulmonary fibrosis, BMI body mass index, COVID-19 corona virus disease 2019, ICU intensive care unit, COPD chronic obstructive pulmonary disease

ISSN: 1465-993X